Nyumc - AIDS-Related Malignancy Consortium

Friedman-Kien, Alvin E.

Abstract

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Cancer Institute (NCI)
• Type: Research Project--Cooperative Agreements (U01)
• Project #: 5U01CA070075-02
• Application #: 2114026
• Study Section: Special Emphasis Panel (SRC (09))
• Project Start: 1995-09-30
• Project End: 1999-07-31
• Budget Start: 1996-08-01
• Budget End: 1997-07-31
• Support Year: 2
• Fiscal Year: 1996

Institution

• Name: New York University
• Department: Dermatology
• Type: Schools of Medicine
• City: New York
• State: NY
• Country: United States
• Zip Code: 10016

Publications

Noy, Ariela; Scadden, David T; Lee, Jeannette et al. (2005) Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol 23:990-8

Miles, Steven A; Dezube, Bruce J; Lee, Jeannette Y et al. (2002) Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma. AIDS 16:421-9

Huang, Y Q; Li, J J; Zhang, W G et al. (1996) Transcription of human herpesvirus-like agent (HHV-8) in Kaposi's sarcoma. J Clin Invest 97:2803-6